Chlorofluorocarbon-free inhalers: Are we ready for the change?

M. R. Partridge, A. A. Woodcock, A. L. Sheffer, Adam Wanner, A. Rubinfeld

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Chlorofluorocarbons (CFCs) damage stratospheric ozone permitting enhanced levels of ultraviolet B radiation to reach the Earth's surface. As a result, production of CFCs is now banned under the Montreal Protocol with the exception of their temporary continued use in pressurized metered dose inhalers used to treat those with airway disorders. Replacement propellants have now been identified and shown to be safe and a major exercise is under way to reformulate the commonly use aerosolized medicines with the new propellants. The new products are now undergoing clinical trials and the first reformulated β-agonist and corticosteroid inhalers have reached the marketplace. The majority of the current products will have been changed over to the new types over the next 3 yrs, and each country will adapt a transition strategy to oversee this process. The politicians, the environmentalists, the pharmaceutical industry and the regulatory authorities have fulfilled their part in this changeover, and respiratory interested health professionals now need to address what this means for them and their patients so that there may be a seamless transition for the millions of people who use inhaled medicines worldwide.

Original languageEnglish
Pages (from-to)1006-1008
Number of pages3
JournalEuropean Respiratory Journal
Volume11
Issue number5
DOIs
StatePublished - May 1 1998

Fingerprint

Chlorofluorocarbons
Nebulizers and Vaporizers
Stratospheric Ozone
Metered Dose Inhalers
Drug Industry
Adrenal Cortex Hormones
Clinical Trials
Exercise
Radiation
Health

Keywords

  • Airway diseases
  • Chlorofluorocarbons
  • Inhalers

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chlorofluorocarbon-free inhalers : Are we ready for the change? / Partridge, M. R.; Woodcock, A. A.; Sheffer, A. L.; Wanner, Adam; Rubinfeld, A.

In: European Respiratory Journal, Vol. 11, No. 5, 01.05.1998, p. 1006-1008.

Research output: Contribution to journalArticle

Partridge, MR, Woodcock, AA, Sheffer, AL, Wanner, A & Rubinfeld, A 1998, 'Chlorofluorocarbon-free inhalers: Are we ready for the change?', European Respiratory Journal, vol. 11, no. 5, pp. 1006-1008. https://doi.org/10.1183/09031936.98.11051006
Partridge, M. R. ; Woodcock, A. A. ; Sheffer, A. L. ; Wanner, Adam ; Rubinfeld, A. / Chlorofluorocarbon-free inhalers : Are we ready for the change?. In: European Respiratory Journal. 1998 ; Vol. 11, No. 5. pp. 1006-1008.
@article{7c64e6ac7c434d01ab554683affdfdea,
title = "Chlorofluorocarbon-free inhalers: Are we ready for the change?",
abstract = "Chlorofluorocarbons (CFCs) damage stratospheric ozone permitting enhanced levels of ultraviolet B radiation to reach the Earth's surface. As a result, production of CFCs is now banned under the Montreal Protocol with the exception of their temporary continued use in pressurized metered dose inhalers used to treat those with airway disorders. Replacement propellants have now been identified and shown to be safe and a major exercise is under way to reformulate the commonly use aerosolized medicines with the new propellants. The new products are now undergoing clinical trials and the first reformulated β-agonist and corticosteroid inhalers have reached the marketplace. The majority of the current products will have been changed over to the new types over the next 3 yrs, and each country will adapt a transition strategy to oversee this process. The politicians, the environmentalists, the pharmaceutical industry and the regulatory authorities have fulfilled their part in this changeover, and respiratory interested health professionals now need to address what this means for them and their patients so that there may be a seamless transition for the millions of people who use inhaled medicines worldwide.",
keywords = "Airway diseases, Chlorofluorocarbons, Inhalers",
author = "Partridge, {M. R.} and Woodcock, {A. A.} and Sheffer, {A. L.} and Adam Wanner and A. Rubinfeld",
year = "1998",
month = "5",
day = "1",
doi = "10.1183/09031936.98.11051006",
language = "English",
volume = "11",
pages = "1006--1008",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - Chlorofluorocarbon-free inhalers

T2 - Are we ready for the change?

AU - Partridge, M. R.

AU - Woodcock, A. A.

AU - Sheffer, A. L.

AU - Wanner, Adam

AU - Rubinfeld, A.

PY - 1998/5/1

Y1 - 1998/5/1

N2 - Chlorofluorocarbons (CFCs) damage stratospheric ozone permitting enhanced levels of ultraviolet B radiation to reach the Earth's surface. As a result, production of CFCs is now banned under the Montreal Protocol with the exception of their temporary continued use in pressurized metered dose inhalers used to treat those with airway disorders. Replacement propellants have now been identified and shown to be safe and a major exercise is under way to reformulate the commonly use aerosolized medicines with the new propellants. The new products are now undergoing clinical trials and the first reformulated β-agonist and corticosteroid inhalers have reached the marketplace. The majority of the current products will have been changed over to the new types over the next 3 yrs, and each country will adapt a transition strategy to oversee this process. The politicians, the environmentalists, the pharmaceutical industry and the regulatory authorities have fulfilled their part in this changeover, and respiratory interested health professionals now need to address what this means for them and their patients so that there may be a seamless transition for the millions of people who use inhaled medicines worldwide.

AB - Chlorofluorocarbons (CFCs) damage stratospheric ozone permitting enhanced levels of ultraviolet B radiation to reach the Earth's surface. As a result, production of CFCs is now banned under the Montreal Protocol with the exception of their temporary continued use in pressurized metered dose inhalers used to treat those with airway disorders. Replacement propellants have now been identified and shown to be safe and a major exercise is under way to reformulate the commonly use aerosolized medicines with the new propellants. The new products are now undergoing clinical trials and the first reformulated β-agonist and corticosteroid inhalers have reached the marketplace. The majority of the current products will have been changed over to the new types over the next 3 yrs, and each country will adapt a transition strategy to oversee this process. The politicians, the environmentalists, the pharmaceutical industry and the regulatory authorities have fulfilled their part in this changeover, and respiratory interested health professionals now need to address what this means for them and their patients so that there may be a seamless transition for the millions of people who use inhaled medicines worldwide.

KW - Airway diseases

KW - Chlorofluorocarbons

KW - Inhalers

UR - http://www.scopus.com/inward/record.url?scp=0031816191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031816191&partnerID=8YFLogxK

U2 - 10.1183/09031936.98.11051006

DO - 10.1183/09031936.98.11051006

M3 - Article

C2 - 9648947

AN - SCOPUS:0031816191

VL - 11

SP - 1006

EP - 1008

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 5

ER -